IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Companyâ€™s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotechâ€™s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
20/07/26	$0.003100	-43.64%	431,318
17/07/26	$0.005500	-8.33%	29,903
16/07/26	$0.006000	+20.00%	1,144,948
15/07/26	$0.005000	-15.25%	278,333
14/07/26	$0.005900	+18.00%	232,203

Delayed Quote OTC Markets

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - OTC Markets Other stock markets 22:59:06 20/07/2026 +03			5-day change	1st Jan Change
0.003100 ^USD	-43.64%		-38.00%	-99.49%

04-06	IO Biotech, Inc.(OTCPK:IOBT.Q) dropped from NASDAQ Composite Index	CI
03-31	IO Biotech, Inc. Filed for Bankruptcy	CI

Market Cap	43.81M 38.4M 35.49M 32.64M 61.59M 4.22B 62.58M 424M 166M 2.07B 165M 161M 7.12B	P/E 2023	-0.95x	P/E 2024	-0.63x
Enterprise Value	-14.31M -12.54M -11.59M -10.66M -20.11M -1.38B -20.44M -139M -54.33M -675M -53.72M -52.55M -2.33B	EV / Sales 2023	-	EV / Sales 2024	-
Free-Float	99.69%	Yield 2023 *	-	Yield 2024	-

04-06	IO Biotech, Inc.(OTCPK:IOBT.Q) dropped from NASDAQ Composite Index	CI
03-31	IO Biotech, Inc. Filed for Bankruptcy	CI
03-31	Io Biotech Inc - files voluntary chapter 7 bankruptcy petition on March 31, 2026 - SEC filing	RE
03-31	IO Biotech, Inc. Terminates Amy Sullivan as Chief Financial Officer on March 31, 2026	CI
03-31	IO Biotech, Inc. Announces Termination of Mai-Britt Zocca as Chief Executive Officer	CI
03-31	IO Biotech, Inc. Announces Management Changes on March 31, 2026	CI
02-17	CNS Pharmaceuticals, Inc. Announces Executive Appointments, Effective March 2, 2026	CI
01-31	Biotech, Inc. Announces Departure of Qasim Ahmad as Chief Medical Officer and Executive Officer, Effective February 15, 2026	CI
01-30	IO Biotech, Inc. Implements Significant Workforce Reduction as Part of Cost-Containment Measures While Exploring Strategic Alternatives	CI
01-26	IO Biotech Shares Fall After Piper Sandler Downgrade	MT
01-26	Piper Sandler Downgrades IO Biotech to Neutral From Overweight, Adjusts Price Target to $0.50 From $3	MT
01-21	Io Biotech announces exploration of strategic alternatives	RE
01-08	Morgan Stanley Downgrades IO Biotech to Underweight, Price Target is $0.36	MT

01-26	IO Biotech Shares Fall After Piper Sandler Downgrade	MT
01-26	Piper Sandler Downgrades IO Biotech to Neutral From Overweight, Adjusts Price Target to $0.50 From $3	MT
01-08	Morgan Stanley Downgrades IO Biotech to Underweight, Price Target is $0.36	MT
30/09/25	IO Biotech Faces Setback as FDA Opposes Cylembio BLA Submission, Morgan Stanley Says	MT
30/09/25	TD Cowen Downgrades IO Biotech to Hold From Buy	MT

IO Biotech, Inc. Stock

Stocks

IOBTQ

US4497781090

Biotechnology & Medical Research

Valuation: IO Biotech, Inc.

Chart: IO Biotech, Inc.

Latest news : IO Biotech, Inc.

Last Transcript: IO Biotech, Inc.

Analysts' recommendations: IO Biotech, Inc.

Press Releases: IO Biotech, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: IO Biotech, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

02-02	IO Biotech Provides Corporate Update	AQ
01-30	IO Biotech Provides Corporate Update	AQ
01-21	IO Biotech Announces Exploration of Strategic Alternatives	AQ
12-16	IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications	AQ
11-26	IO Biotech Announces Participation in Upcoming December Investor Conferences	AQ

1 day	-43.64%
1 week	-38.00%
Current month	-49.18%
1 month	-48.33%
3 months	-49.18%
6 months	-99.40%
Current year	-99.49%

1 week	0		0.01
1 month	0		0.01
Current year	0		0.7
1 year	0		2.79
3 years	0		2.79
5 years	0		17.88
10 years	0		17.88

Manager	Title	Age	Since
Diane McDowell CTO	Chief Tech/Sci/R&D Officer	-	01/10/2021
Devin Smith CMP	Compliance Officer	58	23/01/2023
Maryann Cimino IRC	Investor Relations Contact	-	01/04/2023

Date	Insider	Type	Main position	Quantity	% Market Cap.
6/5/25 A	Heidi Hunter	Free	Director	35,144	0.0533%
6/5/25 A	Kathleen Glaub	Free	Director	35,144	0.0533%
6/5/25 A	David Smith	Free	Director	35,144	0.0533%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IO BIOTECH, INC.	-43.64%	-38.00%	-99.85%	-99.84%	223K
LONZA GROUP AG	-0.49%	-4.01%	-0.84%	+2.28%	48.71B
REVOLUTION MEDICINES, INC.	-3.10%	-1.94%	+370.99%	+572.60%	38.35B
BEONE MEDICINES AG	-0.46%	+2.18%	+5.44%	+61.01%	34.53B
IQVIA HOLDINGS INC.	-1.14%	-1.76%	+26.94%	-9.93%	34.03B
CELLTRION, INC.	-1.82%	-1.43%	+0.52%	+31.85%	26.77B
ASCENDIS PHARMA A/S	-3.54%	-5.08%	-	-	15.64B
MEDPACE HOLDINGS, INC.	-1.82%	-0.43%	+69.28%	+113.82%	15.08B
EUROFINS SCIENTIFIC SE	+1.17%	+2.30%	+15.87%	+18.26%	14.18B
ICON PUBLIC LIMITED COMPANY	-2.25%	+0.05%	+15.77%	-32.83%	12.73B
Average	-5.71%	-4.81%	+44.90%	+73.03%	24B
Weighted average by Cap.	-1.42%	-1.44%	+74.77%	+116.99%

	2023	2024
Net sales	-	-
Net income	-86.08M -75.45M -69.74M -64.14M -121M -8.3B -123M -834M -327M -4.06B -323M -316M -13.99B	-95.49M -83.7M -77.37M -71.15M -134M -9.21B -136M -925M -363M -4.51B -359M -351M -15.52B
Net Debt	-141M -123M -114M -105M -198M -13.57B -201M -1.36B -534M -6.64B -528M -517M -22.87B	-58.12M -50.94M -47.09M -43.3M -81.71M -5.6B -83.02M -563M -221M -2.74B -218M -213M -9.45B